Tech Company M&A Transactions
KAI Pharmaceuticals Acquisition
Based in South San Francisco, KAI Pharmaceuticals was acquired by Amgen. The transaction price was $315 million.
Transaction Overview
Company Name
Acquired By
Announced On
4/10/2012
Transaction Type
M&A
Amount
$315,000,000
M&A Terms
The acquisition will be paid for with all cash.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
270 Littlefield Avenue
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
KAI Pharmaceuticals is a biology-based product-driven pharmaceutical company developing a new class of therapeutics targeting cell-signaling enzymes that affect numerous disease pathways. The company is leveraging its leadership position in protein kinase C (PKC), an important and validated family of kinases, to rapidly advance product candidates into human clinical trials.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steven James
Chief Medical Officer
Gregory Bell
VP - Product Management
Susan Wilson
VP - R & D
Randolph Johnson
Browse more venture capital transactions:
Prev: 4/10/2012: Voci Technologies venture capital transaction
Next: 4/10/2012: Radial Network venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs